Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78
Zhiwen Gu(Shanghai Institute of Materia Medica), Aihua Sun(Beijing Proteome Research Center), Kaikun Xu(Beijing Proteome Research Center), Xianfeng Shao(Qingdao University), Songpeng Yang(Beijing Proteome Research Center), Yuanjun Zhai(Chinese Academy of Medical Sciences & Peking Union Medical College), Yushan Hou(Beijing Proteome Research Center), Fuchu He(Beijing Proteome Research Center), Xinxin Wang(Capital Medical University), Lei Wang(Jiangsu Cancer Hospital), Qian Dong(Daiichi Sankyo (United States)), Cuixiu Lu(Peking University), Jingnan Ye(Beijing Proteome Research Center), Cheng Chang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 37
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|977
Cyclin B1/Cdk1 Coordinates Mitochondrial Respiration for Cell-Cycle G2/M Progression
|Developmental Cell|2014|389
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
|Journal of Clinical Oncology|2023|224
Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response
|Gastroenterology|2009|117